This website uses cookies

This website uses cookies to ensure you get the best experience. By using our website, you agree to our Privacy Policy

International In-house Counsel Journal logoInternational In-house Counsel Journal logo
Back to library search

Creating Efficiencies in Drug Discovery and Development Using Artificial Intelligence

August 2018
Artificial IntelligencePharmaceutical

Abstract

The recent growth of machine learning applications using artificial intelligence (AI), ranging from drug discovery to improvements in patient care, has coincided with increased investments from pharmaceutical and technology companies. Subsequently, there has been a sharp increase in the number of start-ups in this space along with heightened expectations regarding the implications of AI in the health care industry. Given the strict regulations pertaining to drug development and commercial marketing, there are questions as to whether AI can operate within the contours of existing laws or would require novel legal frameworks. This article makes an effort to address those emerging questions.

Author

Portrait image of Priya Mannan
Priya Mannan
Associate General Counsel, Novartis Institutes for Biomedical Research, USA

Haripriya M. Mannan, Associate General Counsel, NIBRI, Cambridge, MA Priya joined Novartis in June 2009 as Associate General Counsel for the Novartis Institutes of Bio Medical Research, Inc. (“NIBR”) in Cambridge, MA. At NIBR, she is the Global Head of Compliance and manages social media, e-commerce, Big data, clinical, ethical, privacy and regulatory matters. Prior to joining NIBR, Priya was a Senior Counsel At Baxter International Inc., in Deerfield, IL. At Baxter, Priya was an FDA Regulatory and Healthcare Compliance attorney and also managed clinical trials and product promotion for the Bioscience business for the company. Priya’s first in-house position was at Pfizer Inc., where she managed in-licensing of phase II and III compounds followed by Medtronic Inc., where she was responsible for clinical, research & development, regulatory and general legal business transactions. Before joining as in-house counsel, Priya was associated with the firms of Reid & Riege and Cantor Colburn based in Hartford, CT where she practiced Healthcare law. She received her undergraduate degree from Madras University majoring in Bio Chemistry and Chemistry and her first law degree also from Madras University. She also received her JD and LLM degrees from St. Louis University School of Law, St. Louis. Missouri.

Company

Novartis Institutes for Biomedical Research

The Novartis Institutes for BioMedical Research (NIBR) is the innovation engine of Novartis. We collaborate across scientific and organizational boundaries, with a focus on powerful new technologies that have the potential to help produce therapeutic breakthroughs for patients.

Related Papers

Operating in a New Frontier: AI Use Cases, Business Risks, and the Regulatory Policy Outlook
We are living in an era where artificial intelligence (AI), specifically generative AI, is reshaping many facets of our daily lives, from the way we work and communicate, to having...Read more
Portrait image of Muyiwa Odeniyide
Muyiwa Odeniyide
Director & Associate General Counsel, Nasdaq , USA
Safeguarding privacy and fairness: the role of AI in fraud detection and AML within the recent EU legal framework developments
Artificial Intelligence (AI) is playing an increasingly pivotal role in fraud detection and anti-money laundering (AML) efforts, offering enhanced capabilities to identify and prevent illicit activities. This paper explores the...Read more
Portrait image of Enik Pogace
Enik Pogace
Head of Employee Relations Division , Bank of Albania, Albania
De-risk as You Democratize: Accelerating Innovation and Ensuring AI Act Readiness in 2025
In the few short years since I wrote an article for the International In-House Counsel Journal advocating for the stronger integration of technology into the strategic planning of in-house legal...Read more
Portrait image of Dirk Naumann
Dirk Naumann
Executive Vice President of Legal, Regulatory, and Compliance, and Chief Legal Officer , Orange Business, International
Patent Strategies for Attenuated Pathogen Vaccines
Malaria is a major health concern for people traveling to and living in malaria-endemic areas, causing 249 million clinical cases and 608,000 deaths in 2022, numbers essentially unchanged over the...Read more
Portrait image of David Dolberg
David Dolberg
Senior Director of Intellectual Property, Sanaria Inc., USA